Patents by Inventor Nicholas J. Papadopoulos

Nicholas J. Papadopoulos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified Chimeric Polypeptides With Improved Pharmacokinetic Properties
    Publication number: 20100221782
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
    Type: Application
    Filed: March 1, 2010
    Publication date: September 2, 2010
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
  • Methods of inhibiting ascites formation with modified chimeric VEGF polypeptides
    Patent number: 7704500
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: April 27, 2010
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
  • VEGF-Binding Fusion Proteins and Therapeutic Uses Thereof
    Publication number: 20100087632
    Abstract: Fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.
    Type: Application
    Filed: November 23, 2009
    Publication date: April 8, 2010
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Thomas J. Daly, James P. Fandl, Nicholas J. Papadopoulos
  • High Affinity Human Antibodies to Human IL-4 Receptor
    Publication number: 20100047254
    Abstract: The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
    Type: Application
    Filed: September 10, 2009
    Publication date: February 25, 2010
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. Martin, Tammy T. Huang, Jeanette L. Fairhurst, Nicholas J. Papadopoulos
  • High Affinity Human Antibodies to Human IL-4 Receptor
    Publication number: 20100021476
    Abstract: The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
    Type: Application
    Filed: September 4, 2009
    Publication date: January 28, 2010
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Diana M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos
  • VEGF-binding fusion proteins
    Patent number: 7635474
    Abstract: Nucleic acid molecules encoding fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: December 22, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Thomas J. Daly, James P. Fandl, Nicholas J. Papadopoulos
  • High affinity human antibodies to human IL-4 receptor
    Patent number: 7608693
    Abstract: An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R?) with high affinity (KD), capable of blocking hIL-4 and hIL-13 activity.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: October 27, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. Martin, Tammy T. Huang, Jeanette L. Fairhurst, Nicholas J. Papadopoulos
  • High affinity human antibodies to human IL-4 receptor
    Patent number: 7605237
    Abstract: An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R?) with an affinity constant (KD) of less than 200 pM, as measured by surface plasmon resonance.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: October 20, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Marcela Torres, Kevin J. Pobursky, Raymond W. Leidich, Joan A. Windsor, Warren R. Mikulka, Diana M. Ahrens, Ergang Shi, Nicholas J. Papadopoulos
  • High affinity antibodies to human IL-6 receptor
    Patent number: 7582298
    Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: September 1, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
  • Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties
    Publication number: 20090155899
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
    Type: Application
    Filed: December 15, 2008
    Publication date: June 18, 2009
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
  • HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4
    Publication number: 20090142354
    Abstract: An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds dimeric hDll4 with an affinity of 75 pM or better, as measured by surface plasmon resonance.
    Type: Application
    Filed: February 13, 2009
    Publication date: June 4, 2009
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Joel H. Martin, Eric Smith, Irene Noguera-Troise, Gavin Thurston
  • Human antibodies to human delta like ligand 4
    Patent number: 7534868
    Abstract: An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDII4) and blocks hDII4 binding to a Notch receptor. The human anti-hDII4 antibody or antibody fragment binds dimeric hDII4 with an affinity of 75 pM or better, as measured by surface plasmon resonance.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: May 19, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Joel H. Martin, Eric Smith, Irene Noguera-Troise, Gavin Thurston
  • Modified chimeric polypeptides with improved pharmacokinetic properties
    Patent number: 7524499
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: April 28, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
  • Use of VEGF inhibitors for treatment of eye disorders
    Patent number: 7521049
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: April 21, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Stanley J. Wiegand, Nicholas J. Papadopoulos, George D. Yancopoulos, James P. Fandl, Thomas J. Daly
  • Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties
    Publication number: 20090081217
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
    Type: Application
    Filed: April 14, 2008
    Publication date: March 26, 2009
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
  • High Affinity Human Antibodies to Human IL-4 Receptor
    Publication number: 20090074793
    Abstract: An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R?) with high affinity (KD), capable of blocking hIL-4 and hIL-13 activity.
    Type: Application
    Filed: October 29, 2008
    Publication date: March 19, 2009
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Joel H. Martin, Tammy T. Huang, Jeanette L. Fairhurst, Nicholas J. Papadopoulos
  • IGF-1 Fusion Polypeptides and Therapeutic Uses Thereof
    Publication number: 20090069235
    Abstract: A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.
    Type: Application
    Filed: June 6, 2008
    Publication date: March 12, 2009
    Inventors: David J. GLASS, George D. Yancopoulos, Thomas J. Daly, Nicholas J. Papadopoulos
  • VEGF-Binding Fusion Proteins and Therapeutic Uses Thereof
    Publication number: 20090062200
    Abstract: Nucleic acid molecules encoding fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.
    Type: Application
    Filed: June 9, 2008
    Publication date: March 5, 2009
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Thomas J. DALY, James P. Fandl, Nicholas J. Papadopoulos
  • Human antibodies to human delta like ligand 4
    Patent number: 7488806
    Abstract: An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds hDll4 with an affinity of 300 pM or better, as measured by surface plasmon resonance.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: February 10, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Joel H. Martin, Eric Smith, Irene Noguera-Troise, Gavin Thurston
  • HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4
    Publication number: 20090017035
    Abstract: An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds hDll4 with an affinity of 300 pM or better, as measured by surface plasmon resonance.
    Type: Application
    Filed: October 3, 2008
    Publication date: January 15, 2009
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Nicholas J. Papadopoulos, Joel H. Martin, Eric Smith, Irene Noguera-Troise, Gavin Thurston